Shelton Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Shelton Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,300	Closed	-$671K	–	681
2022 Q3	$671K	Sell	45,300 -7,700	-15%	-$129K	0.03%	273
2022 Q2	$834K	Hold	53,000	–	–	0.04%	270
2022 Q1	$1.43M	Buy	53,000 +5,000	+10%	+$128K	0.05%	245
2021 Q4	$1.78M	Hold	48,000	–	–	0.06%	241
2021 Q3	$2.29M	Buy	48,000 +10,000	+26%	+$448K	0.09%	215
2021 Q2	$1.29M	Buy	38,000 +7,800	+26%	+$264K	0.05%	259
2021 Q1	$1.25M	Buy	+30,200	New	+$1.8M	0.04%	275

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Shelton Capital Management's ARCT Position: Q4 2022 in Review

Shelton Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 45,300 shares — an estimated $671K sold.

Shelton Capital Management first reported a position in ARCT in Q1 2021 and held it in 7 quarters. The position peaked at $2.29M in Q3 2021. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

Shelton Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
Shelton Capital Management sold 45,300 Arcturus Therapeutics shares in Q4 2022, an estimated $671K.
Shelton Capital Management first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 7 quarters.
Shelton Capital Management's Arcturus Therapeutics position peaked at $2.29M in Q3 2021.
111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on Shelton Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.